|
Market Closed -
Nasdaq Stockholm
17:00:00 19/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 21.45 SEK | +7.25% |
|
+15.57% | -5.09% |
| 08-19 | Synact Pharma signs term sheet with Hipolabor on resomelagon in Brazil | FW |
| 08-06 | SynAct Pharma Secures Appellate Board Backing in US Patent Application | MT |
| Market Cap | 1.2B 127M 109M 102M 93.39M 176M 12.15B 179M 470M 6.09B 477M 467M 20.14B | P/E 2026 * |
-14.4x | P/E 2027 * | -28.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1.18B 125M 107M 100M 92.04M 173M 11.97B 176M 464M 6B 470M 460M 19.85B | EV / Sales 2026 * |
8.53x | EV / Sales 2027 * | 58x |
| Free-Float |
70.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: SynAct Pharma AB
| 1 day | +7.25% | ||
| 1 week | +15.57% | ||
| Current month | +17.47% | ||
| 1 month | +8.99% | ||
| 3 months | +51.91% | ||
| 6 months | +12.07% | ||
| Current year | -5.09% |
| 1 week | 19.02 |  | 22.2 |
| 1 month | 17.08 | | 22.2 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 124.6 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.8 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 31/12/2013 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 28/02/2026 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 14/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 19/03/2024 |
Anders Kronborg
CHM | Chairman | 62 | 19/03/2024 |
Sten Scheibye
BRD | Director/Board Member | 74 | 19/03/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06/03/26 | Buy | Chief Operating Officer | 2,750 | 0.0052% | ||
| 31/12/25 | Buy | Chief Technology Officer | 3,529 | 0.0066% | ||
| 22/12/25 | Buy | Chairman | 3,470 | 0.0065% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.25% | +15.57% | +15.45% | -77.44% | 117M | |
| +4.46% | +5.38% | +83.42% | +134.31% | 1,093B | |
| +0.85% | +5.24% | +55.13% | +58.51% | 653B | |
| +2.72% | +6.35% | +28.76% | +77.15% | 458B | |
| +1.80% | -0.41% | +43.52% | +44.05% | 355B | |
| +1.24% | +1.00% | +26.84% | +42.21% | 294B | |
| +2.07% | +1.74% | +2.66% | +13.06% | 248B | |
| +4.02% | +6.77% | +51.17% | +68.96% | 230B | |
| +1.05% | -2.52% | -13.83% | -52.13% | 203B | |
| +2.90% | +8.71% | +25.10% | +94.52% | 178B | |
| Average | +2.45% | +1.86% | +31.82% | +40.32% | 371.06B | |
| Weighted average by Cap. | +1.53% | +1.45% | +47.89% | +73.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 139M 14.68M 12.59M 11.76M 10.79M 20.29M 1.4B 20.62M 54.33M 704M 55.12M 53.92M 2.33B | 21.15M 2.24M 1.92M 1.79M 1.64M 3.09M 214M 3.14M 8.28M 107M 8.4M 8.22M 355M |
| Net income | 52.18M 5.52M 4.74M 4.42M 4.06M 7.63M 528M 7.75M 20.43M 265M 20.73M 20.28M 875M | -26.04M -2.76M -2.36M -2.21M -2.03M -3.81M -263M -3.87M -10.2M -132M -10.35M -10.12M -437M |
| Net Debt | -17.48M -1.85M -1.59M -1.48M -1.36M -2.56M -177M -2.6M -6.84M -88.66M -6.94M -6.79M -293M | 24.86M 2.63M 2.26M 2.11M 1.93M 3.63M 251M 3.69M 9.73M 126M 9.88M 9.66M 417M |
Employees
8
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/08/26 | SEK 21.45 | +7.25% | 447,400 |
| 18/08/26 | SEK 20.00 | +1.11% | 59,018 |
| 17/08/26 | SEK 19.78 | -0.80% | 109,127 |
| 14/08/26 | SEK 19.94 | -1.04% | 124,770 |
| 13/08/26 | SEK 20.15 | +4.40% | 180,150 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Select your edition
All financial news and data tailored to specific country editions
